Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
ConclusionThese safety and efficacy results support dupilumab as a continuous long-term treatment for adults with moderate-to-severe AD.Trial RegistrationClinicalTrials.gov: NCT01949311.Video abstractDupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis (MP4 139831 kb)
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research
More News: Common Cold | Conjunctivitis | Dermatitis | Dermatology | Eczema | Headache | Herpes | Migraine | Respiratory Medicine | Skin | Study